Kinnos Unveils Highlight® Wipes Technology at TechCrunch Disrupt SF 2017
NEW YORK / SAN FRANCISCO, September 18, 2017 – Hundreds of startups, entrepreneurs, and investors will gather at TechCrunch’s annual flagship event, Disrupt SF, to witness the debut of game-changing technologies and companies. This year, Kinnos Inc. was selected as one of three Featured Pavilion companies in the Health & Biotech category in Startup Alley, the heart of early-stage innovation at Disrupt SF.
Today, Kinnos unveils its Highlight® Wipes technology to combat healthcare-associated infections (HAIs) and antimicrobial resistance in hospitals and other healthcare settings. Every year, 1 out of every 25 patients will contract an HAI, leading to 75,000 deaths and >$28 billion lost in the US healthcare system alone. Despite an abundance of disinfection and sterilization technologies available on the market, studies have shown that only half of surfaces are properly decontaminated in most healthcare facilities. Disinfectant wipes are often used to clean surfaces in patient rooms; however, human error can lead to noncompliance with fully covering surfaces and waiting sufficient contact time for pathogens to be inactivated. These errors in compliance render disinfectants ineffective and lead to the transmission of disease.
Originally developed for frontline workers in the Ebola outbreak, Kinnos’s patent-pending color change additive has been incorporated into the revolutionary Highlight® Wipes lid. The device attaches onto commercially available bleach wipe canisters that are widely used to kill robust pathogens such as C. difficile, MRSA, and norovirus. As a wipe is pulled through, the wipe is imbued with Highlight®, allowing healthcare personnel to colorize a surface when wiping to ensure complete coverage. The color subsequently fades from blue to transparent to provide real-time visual feedback for when decontamination is done. Unlike other disinfection technologies that seek to add time-consuming and expensive supplementary processes, Highlight fundamentally improves the basics of environmental cleaning for training and daily use.
“It has become increasingly clear that the process of disinfection, not just the disinfectant that is being used, is a critical part of any infection control and prevention program,” said Jason Kang, Co-Founder and CEO of Kinnos. “Highlight® bridges the gap between simply having a disinfectant and actually being able to use it effectively by enforcing real-time compliance and real-time quality control.”
Highlight® Wipes will be piloted at leading medical institutions around the United States and will be commercially available in 2018. Hospital systems and other healthcare facilities interested in using Highlight® Wipes should reach out to the contact information provided below.About Kinnos Inc.
Kinnos is a New York-based company that aims to raise the standard of infection prevention to protect healthcare workers, patients, and the general public from infection. Their first product, Highlight®, is a patent-pending point-of-use additive that greatly improves visibility, coverage, and end-user compliance of disinfectants. Highlight® is used by HazMat and biosafety units, was a winner of the USAID Fighting Ebola Grand Challenge, and has been field-tested by NGOs and healthcare workers in Liberia, Guinea, and Haiti. For more information, visit: www.kinnos.usAbout TechCrunch Disrupt
TechCrunch Disrupt SF 2017 is TechCrunch’s 11th annual conference in San Francisco. The format combines top thought-leader discussions with new product and company launches. Morning executive discussions debate technology-driven disruptions in many industries, while the afternoons are reserved for the Startup Battlefield, where 20+ new companies will launch for the first time onstage, selected to present from numerous applications received from around the world. The winning company will receive a $50,000 grand prize and the Disrupt Cup at the conclusion of the conference. The conference is September 18-20th, 2017 at Pier 48 in San Francisco.
Kinnos Inc. firstname.lastname@example.org